Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
about
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachRecent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingStructural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic MacrocyclesStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4Signaling, Regulation, and Specificity of the Type II p21-activated KinasesMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionPerspective on computational and structural aspects of kinase discovery from IPK2014Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinomeDFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitorsCrystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.The ins and outs of selective kinase inhibitor development.Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.Dynamics of protein kinases: insights from nuclear magnetic resonance.Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitorsDetection of Ligand-induced Conformational Changes in the Activation Loop of Aurora-A Kinase by PELDOR SpectroscopyDual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors.Generation of small molecules to interfere with regulated necrosis.The hunt for antimitotic agents: an overview of structure-based design strategies.Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A.From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.KLIFS: a structural kinase-ligand interaction database.Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions.Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.The target landscape of clinical kinase drugs.MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
P2860
Q24672143-D500C837-59DD-494A-B330-427367E35E74Q26774478-696C431B-A2F8-4979-8268-03A283CBD5F1Q27727987-92ACB240-4EB4-4B29-8570-AE5163474123Q27853214-19104C7A-6577-44A9-A17F-F2AB3995F457Q28078574-D585DF15-CCD7-4258-A984-7F4385B00FF1Q28083745-84563894-0AE2-44AC-B21D-84E0B01490C8Q28548366-8FB6C90F-D4C2-42EC-8F78-48F7C4DDFF4CQ30373565-80161FD8-0017-4051-8978-C5EBD481C48CQ33811883-978324F0-C822-4DED-9F25-7CCF68358D3BQ34992475-4984B29F-0396-4FB8-9ABF-9CCCD83C0FC4Q35250091-0F636CB1-3C6A-4FF0-8352-A4405A383148Q35493874-8915608B-2879-45C4-91F8-47407C93D7F7Q35814547-DBFED156-DA56-4392-8B96-DB8573A3743AQ35828387-631F46AA-207B-465F-8A96-3E96DACCD81FQ35909096-172248E5-5040-47BA-8AC6-F21365561831Q36084130-176B0F8A-AE2C-470D-B81E-60AADBCD0B95Q36280842-7FFC2EDA-1C5D-4DE9-931D-35AC2C400089Q36389868-C15214E1-16BB-41BC-A488-C7D342986E9BQ36420336-E3EF7E73-99B8-403A-98BA-9CF785363FADQ36493862-4BEE1BF7-6D1E-41BA-A6CE-C54688A7095DQ37515396-C667789A-FE3D-4063-AA7E-7DAB6C3EF498Q38637354-46DC1416-BCD8-4277-860A-B906F021CF6FQ38761171-D53C416E-06B8-4029-B417-6603443BFDC3Q38773791-60C18CCA-FEBC-407C-A9AB-3569EDFC2551Q38799144-6F069212-693D-4D97-9614-7C08531A5B7BQ38808120-71E84098-EC52-4C32-9B97-B1F63D3AAC47Q38893229-F6583B11-7EC8-47BE-BDAE-3C41E048F073Q38959137-068C898D-FE79-47C2-98AF-D7A8EF9EE9A0Q38989374-24877D37-F6E7-4C8A-9F23-164BAC7376FCQ38999228-B3BC4057-C254-445E-824F-FE0DA8D1046FQ39120175-002370D6-8D3E-4A30-B03B-ABC517F5124EQ39154885-83F94AED-5AD6-4F5A-ADDA-69D5FEE6958BQ39580226-DFEE8F18-CF92-4FC7-AD9F-9AA12C3B3F11Q40030976-89421A36-C0FD-4256-92EE-4314DCE4D319Q40397851-2FA0FC78-18BA-44A0-A474-05B1B020A023Q41717003-9CF695A1-6D50-4D3F-85CF-03992C7F1801Q42023703-32AE071B-B7AE-44BB-9412-4F0B5ECE4DECQ46173337-CB5947E4-719A-440D-BC4B-A07AE6E470A8Q47345032-79B389E5-3B87-4A15-9EE0-5EF3126C10D6Q48282223-575B5EE0-0A3B-4D16-94A6-3930E7DD69C2
P2860
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Exploration of type II binding ...... ibitor focused drug discovery?
@ast
Exploration of type II binding ...... ibitor focused drug discovery?
@en
Exploration of type II binding ...... ibitor focused drug discovery?
@nl
type
label
Exploration of type II binding ...... ibitor focused drug discovery?
@ast
Exploration of type II binding ...... ibitor focused drug discovery?
@en
Exploration of type II binding ...... ibitor focused drug discovery?
@nl
prefLabel
Exploration of type II binding ...... ibitor focused drug discovery?
@ast
Exploration of type II binding ...... ibitor focused drug discovery?
@en
Exploration of type II binding ...... ibitor focused drug discovery?
@nl
P2093
P2860
P921
P356
P1433
P1476
Exploration of type II binding ...... ibitor focused drug discovery?
@en
P2093
P2860
P304
P356
10.1021/CB500129T
P407
P577
2014-06-20T00:00:00Z